A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma Clinical Trial

— CARTIFAN-1  

Official title:

A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03758417
• Other study ID #: CR108494
• Secondary ID: 68284528MMY2002
• Status: Recruiting
• Phase: Phase 2
• Start date: January 23, 2019
• Est. completion date: February 16, 2026

Study information

• Verified date: December 2022
• Source: Nanjing Legend Biotech Co.
• Contact: Xiaohu Fan
• Phone: 13851733397
• Email: frank.fan[@]legendbiotech.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of LCAR-B38M chimeric antigen receptor T (CAR-T) cells.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 130
• Est. completion date: February 16, 2026
• Est. primary completion date: February 16, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria

• Measurable disease at Screening

• Received at least 3 prior lines of treatment for multiple myeloma

a) Undergone at least 1 complete cycle of treatment for each line, unless progressive disease (PD) was documented by IMWG criteria as the best response to the regimen

• Received a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD)

• Participant must have documented evidence of progressive disease based on investigator's determination of response consistent with IMWG criteria on or within 12 months of their last regimen. Non-responsive disease is defined as either failure to achieve minimal response or development of progressive disease (PD) while on therapy. Also, participants with documented evidence of PD disease (as above) within the previous 6 months and who are refractory or non-responsive to their most recent line of treatment afterwards are eligible

• Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0 or 1

Exclusion Criteria:

• Prior treatment with chimeric antigen receptor T (cells) CAR-T therapy directed at any target

• Any therapy that is targeted to B-cell maturation antigen (BCMA)

• The following cardiac conditions: a) New York Heart Association (NYHA) stage III or IV congestive heart failure b) Myocardial infarction or coronary artery bypass graft (CABG) 6 months prior to enrollment c) History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be vasovagal in nature or due to dehydration d) History of severe non-ischemic cardiomyopathy e) Impaired cardiac function (left ventricular ejection fraction [LVEF] less than [<]45%) as assessed by echocardiogram or multiple-gated acquisition (MUGA) scan (performed less than or equal to (<=) 8 weeks of apheresis)

• Have received a cumulative dose of corticosteroids equivalent to greater than or equal to(>=)70 milligram (mg) of prednisone within 7 days prior to apheresis

• Diagnosed or treated for invasive malignancy other than multiple myeloma, except:

1. Malignancy treated with curative intent and with no known active disease present for greater than or equal to (>=) 2 years before enrollment; or

2. Adequately treated non-melanoma skin cancer without evidence of disease

• Prior antitumor therapy with insufficient washout period

• Toxicity from previous anticancer therapy must resolve to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy

• Received either of the following:

1. An allogeneic stem cell transplant for multiple myeloma

2. An autologous stem cell transplant less than or equal to (<=) 12 weeks before apheresis

• Known active, or prior history of, central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Biological:
• LCAR-B38M CAR-T Cell
Participants will receive LCAR-B38M CAR-T cells as a single infusion which consists of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).

Locations

Country	Name	City	State
China	Peking University Third Hospital	Beijing	Beijing
China	West China Hospital, Sichuan University	Chengdu	Sichuan
China	Fujian Medical University Union hospital	Fuzhou	Fujian
China	Sun Yat -Sen University Cancer Center	Guandong	Guangzhou
China	The First Affiliated Hospital, Medical School of Zhejiang University	Hangzhou	Zhejiang
China	Jiangsu Province Hospital	Nanjing	Jiangsu
China	Nanjing Drum Tower Hospital	Nanjing	Jiangsu
China	Ruijin Hospital, Shanghai Jiao Tong University	Shanghai	Shanghai
China	Shanghai Changzheng Hospital	Shanghai	Shanghai
China	Shanghai Fourth People Hospital	Shanghai	Shanghai
China	The Second Affiliated Hospital of Xi'an Jiaotong University	Xi'an	Shanxi

Sponsors (2)

Lead Sponsor	Collaborator
Nanjing Legend Biotech Co.	Janssen Research & Development, LLC

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate (ORR)	The ORR is defined as the percentage of participants who achieve at least a partial response (PR) or better according to international myeloma working group (IMWG) criteria.	Minimum 2 years after LCAR-B38M chimeric antigen receptor T (CAR-T) infusion (Day 1)
Secondary	Number of Participants With Adverse Events	An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Chimeric Antigen Receptor T (CAR-T) Positive Cell Concentration	Venous blood samples will be collected for measurement of CAR-T positive cellular concentration.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Transgene Levels of LCAR-B38M CAR-T Cells	Transgene Levels of LCAR-B38M CAR-T Cells using sensitive assay methods will be assessed.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Systemic Cytokine Concentrations	Serum cytokine concentrations such as Interleukin [IL]-6, IL-15, IL-10 will be measured for biomarker assessment.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Number of Participants With Anti- LCAR-B38M CAR-T Cell Antibodies	Number of participants with anti- LCAR-B38M CAR-T cell antibodies will be evaluated.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Percentage of Participants with Very Good Partial Response (VGPR) or Better Rate	The VGPR or better rate, defined as the percentage of participants achieving VGPR and complete response (CR) (including stringent complete response [sCR]) according to IMWG criteria during or after the study treatment. IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or greater than or equal to (>=) 90 percent (%) reduction in serum Mprotein plus urine M-protein less than (<) 100 milligram (mg)/24 hours, CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas and <5% plasma cells (PCs) in bone marrow. sCR: CR plus normal free light chain (FLC) ratio, and absence of clonal PCs by immunohistochemistry (IHC), immunofluorescence for 2 to 4 color flow cytometry.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Percentage of Participants with Complete Response (CR)	Complete response is based on serum M-Protein and bone marrow assessments as per IMWG criteria.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Percentage of Participants with Negative Minimal Residual Disease (MRD)	Minimal residual disease negative rate is defined as the percentage of participants who achieve MRD negative status by the respective time point. MRD will be assessed by bone marrow 8-colored flow cytometry.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Percentage of Participants who Achieve Clinical Benefit	Clinical Benefit Rate is defined as the percentage of participants who achieve ORR (sCR + CR + VGPR + PR) and minimal response (MR) as per IMWG criteria.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Duration of Response (DOR)	Duration of response (DOR) will be calculated among responders (with a PR or better response) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG criteria or death due to any cause, whichever occurs first.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Time to Response (TTR)	Time to response (TTR) is defined as the time between date of the initial infusion of LCAR-B38M CAR-T cells and the first efficacy evaluation that the participant has met all criteria for PR or better.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Progression-Free Survival (PFS)	PFS defined as time from date of initial infusion of LCAR-B38M CAR-T cells to date of first documented disease progression, defined in the IMWG criteria, or death due to any cause, whichever occurs first.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Overall survival (OS)	Overall survival (OS) is measured from the date of infusion of the LCAR-B38M CAR-T cells to the date of the participant's death.	Mnimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Levels of CAR-T cell Activation Markers	Levels of CAR-T cell Activation Markers like CD4+, CD8+, and CD25+ will be assessed. An evaluation of cell populations may be performed by flow cytometry.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Levels of LCAR-B38M CAR-T cell Expansion (proliferation)	Levels of LCAR-B38M CAR-T cell expansion (proliferation) will be reported.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Levels of LCAR-B38M CAR-T Persistence	Levels of LCAR-B38M CAR-T persistence will be evaluated via monitoring CAR-T positive cell counts and CART transgene levels.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Percentage of Participants with Stringent Complete Response (sCR)	Stringent Complete Response (sCR) is based on serum M-Protein and bone marrow assessments as per IMWG criteria for complete response(CR) plus normal free light chain (FLC) ratio, and absence of clonal PCs by immunohistochemistry(IHC), or 2 to 4 color flow cytometry.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Circulating Soluble B-Cell Maturation Antigen (sBCMA) Levels	Blood samples will be collected for measurement of sBCMA level.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)
Secondary	Percent Reduction in BCMA Expression Cells	Percent reduction in BCMA Expression Cells will be measured.	Minimum 2 years after LCAR-B38M CART infusion (Day 1)